MILLBURN, N.J., Feb. 14 /PRNewswire/ -- Defined Health, a leading business development strategy consultancy to pharma, biotech and healthcare investment executives, announced today that the fifth annual Therapeutic Insight Conference (“TI2005") will take place on May 1-3, 2005, at the Ritz-Carlton, Boston.
Confirmed TI2005 speakers to date are as follows: Karen Bernstein, PhD, Chairman and Editor-in-Chief, BioCentury Publications (KEYNOTE) Arthur L. Caplan, Ph.D., Emmanuel and Robert Hart Professor of Bioethics, Center for Bioethics & Department of Medical Ethics, University of Pennsylvania Michael D. Clayman, MD, Vice President, Lilly Research Laboratories, Eli Lilly Dino Dina, MD, President, CEO, and Director, Dynavax Stuart N. Farrow, BSc, PhD, Asthma & Biology, Respiratory & Inflammation, Center of Excellence for Drug Discovery, GlaxoSmithKline plc Howard Fillit, MD, Executive Director, The Institute for the Study of Aging Frederick Frank, Vice Chairman and Director, Lehman Brothers James A. Geraghty, Senior Vice President, Cardiovascular Division, Genzyme Thomas D. Giles, MD, Professor of Medicine and Director of Cardiovascular Research, Louisiana State University Medical School, Department of Medicine, Cardiovascular Research Laboratory Robert H. Glassman, MD, Director, Healthcare Investment Banking, M & A Group, Merrill Lynch Mitchell H. Gold, MD, President & Chief Executive Officer, Dendreon George S. Golumbeski, PhD, Vice President Business Development Licensing & Strategy - Oncology, Novartis Pharmaceuticals Corp. Thomas Hofstaetter, PhD, Senior Vice President Corporate Business Development, Wyeth Pharmaceuticals Tamar D. Howson, Senior Vice President, Corporate & Business Development, Bristol-Myers Squibb Company Steven M. Kelsey, MD, FRCP, FRCPath Group Director, Genentech BioOncology Arthur M. Krieg, MD, Chief Scientific Officer, Coley Pharmaceutical Group Jonathan S. Leff, Managing Director, Warburg Pincus Jeremy Levin, PhD, Global Head, Strategic Alliances, Novartis Institutes Biomedical Research Clive A. Meanwell, MD, Chairman & CEO, The Medicines Company Arlene Morris, President & CEO, Affymax Paul Nakagaki, PhD, Head of Pharma Research Strategy, Roche Elizabeth Ofili, MD, MPH, FACC, Professor of Medicine, Chief of Cardiology, and Director, Clinical Research Center, Morehouse School of Medicine Menelas Pangalos, PhD, VP Neurosciences Drug Discovery, Wyeth Rodney Pearlman, PhD, Co-Founder, President and CEO, Saegis Pharmaceuticals Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School Neal Rosen, MD, PhD, Professor of Medicine, Memorial Sloan Kettering Cancer Center Edward C. Saltzman, President, Defined Health Bruce J. Seeley, Sr. Director Commercial Development & Business Unit Operations, Genentech BioOncology Thomas Sheehan, Managing Director, Morgan Stanley
TI2005 features a series of plenary sessions addressing overall industry issues, as well as therapeutic category focused panels. Plenary sessions will look at business model interrelationships among the various industry sectors, value drivers for pharma, biotech and specialty pharma moving forward, the industry’s public image, and the future of complex therapeutics such as cell and gene therapies, or dendritic vaccines that will require integration of processing of patient materials and a service component. Therapy area focused sessions will examine “game changing” considerations for sustainable franchises in Cardiovascular/Metabolics, Oncology, Neurodegenerative Diseases and Respiratory Disease. Dr. Arthur Caplan, PhD, of the University of Pennsylvania, a renowned expert on biotechnology and bioethics, will present a keynote entitled, “Drug Safety, Blockbusters, Omics & Ethics: Implications for Drug Development & Commercialization.”
Therapeutic Insight 2005 is sponsored by Defined Health, Communitech Market Intelligence and Goodwin Procter LLP. To register, or for more information, please contact Communitech (914) 245-7764, http://www.cmius.com/ , or Defined Health (973) 921-2850, http://www.definedhealth.com/ .
About Defined Health
Founded more than 20 years ago, Defined Health (http://www.definedhealth.com/) is a leading biopharmaceutical business development strategy consulting firm whose clients include a mix of pharma, emerging and specialty pharma, biotech, and healthcare investment companies. Defined Health’s consultants hold advanced degrees in science, medicine and business, and have industry experience in business development, commercial evaluation, finance, licensing, drug discovery and R&D. Defined Health’s clients include more than half of the world’s top 20 pharmaceutical companies.
Contact: Ginny E. Llobell Vice President Defined Health 973-921-2850
Defined Health
CONTACT: Ginny E. Llobell, Vice President, Defined Health,+1-973-921-2850
